The FDA has once again rejected a T cell therapy for a rare and serious transplant complication related to Epstein-Barr virus.
Atara Biotherapeutics’ treatment, called tabelecleucel or tab-cel, is designed to treat patients with Epstein …
Read More from Endpoints News